Federal Register #DEA-1781

DEA Notice on Groff Health Inc.’s Application to Import Controlled Substances

The DEA notice concerns Groff Health Inc.’s application to import specified controlled substances; it is not a procurement solicitation or award. - Government offices: U.S. Department of Justice (DOJ), Drug Enforcement Administration (DEA). - Applicant: Groff Health Inc. - Substances named in the application: ibogaine, 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and psilocyn. - Proposed scope: Import bulk substances for internal research, clinical trials, analytical purposes, and distribution to customers. - Important limitations: The requested registration would not authorize other activities involving the listed drug codes or imports of finished dosage forms for commercial sale. - Procurement status: No products or services are being purchased; no quantities, part numbers, contract value, or performance period are specified.

Description

Groff Health Inc. applied to the Drug Enforcement Administration to register as an importer of basic classes of controlled substances, including ibogaine, 3,4-methylenedioxymethamphetamine, psilocybin, and psilocyn. The company plans to import bulk substances for internal research, clinical trials, analytical purposes, and distribution to its customers. The notice states that no other activities for these drug codes are authorized and that the registration does not authorize importing finished dosage forms for commercial sale. Comments, objections, and hearing requests are due by November 18, 2026.

View original listing